Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$18.81B
Positions
101
New
8
Increased
21
Decreased
10
Sold Out
19
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $18.81B across 101 positions in their Q4 2019 SEC 13F filing (period ending 2019-12-31). The top 10 positions account for 85.0% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | $5.72B | 30.41% | - |
| 2 | INCYIncyte Corporation | $2.79B | 14.84% | +0.0% |
| 3 | ONCBeiGene, Ltd. | $1.95B | 10.38% | - |
| 4 | ACADACADIA Pharmaceuticals Inc. | $1.75B | 9.29% | - |
| 5 | ALXNAlexion Pharmaceuticals, Inc. | $893.11M | 4.75% | - |
| 6 | KODKodiak Sciences Inc. | $794.85M | 4.23% | +20.8% |
| 7 | Amarin Corporation plc | $739.61M | 3.93% | -17.0% |
| 8 | BMRNBioMarin Pharmaceutical Inc. | $641.67M | 3.41% | - |
| 9 | ASNDUSDAscendis Pharma A/S | $471.65M | 2.51% | - |
| 10 | EXKExact Sciences Corporation | $239.13M | 1.27% | New |
| Stock | Value | Shares |
|---|---|---|
| EXKExact Sciences Corporation | $239.13M | 2,585,791 |
| AUPHAurinia Pharmaceuticals Inc. | $34.48M | 1,701,929 |
| Frequency Therapeutics, Inc. | $21.59M | 1,231,433 |
| Urovant Sciences Ltd. | $15.51M | 1,000,000 |
| CABACabaletta Bio, Inc. | $8.89M | 636,363 |
| RETAEURReata Pharmaceuticals, Inc. | $8.38M | 40,983 |
| Millendo Therapeutics, Inc. | $5.62M | 833,333 |
| OPHTEURIVERIC bio, Inc. | $1.22M | 141,750 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.